BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:45 PM
 | 
Oct 20, 2009
 |  BC Extra  |  Company News

Biogen Idec discloses pipeline setbacks

Biogen Idec Inc. (NASDAQ:BIIB) disclosed setbacks for three compounds during its 3Q09 earnings conference call on Tuesday: ocrelizumab, lumiliximab and galiximab. The biotech said that it placed the Phase III FILM trial of ocrelizumab to treat methotrexate-naive rheumatoid arthritis patients on clinical hold...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >